Dr Murli, is a highly respected doctor across streams and nationalities who has developed his own cult due to his sincere aptitude and noble attitude while providing out of box and Class Medical Solution irrespective of classes being privileged and/or unprivileged whatsoever. This has resulted in a huge fan following for him across UAE, GCC and India especially for his modesty and out of box availability to stand by the suffering humanities without caring for Socio-Economic dimension and timing. His immense stamina for sustained hard work during Covid 19 has been a classic example of his Medical Philanthropy. His Mid Night’s to Morning consultancy to the suffering population back home in India (on line) was his SIGNATURE HUMANITARIAN EXPEDITION beyond Dynamics.

Dr.Murli belongs to a family of Doctors and holds a series of Medical Qualifications and Accolades. He finished his Cardiology Fellowship in 2002 from SJIC, Bangalore. He had undergone applied trainings in Complex Angioplasty from Buenos Aires, Argentina and Osaka, Japan. He is a credible Rotarian of Rotary International in India. He is a forward-looking member in Cardiological Society of India and is presently, Vice President of CSI, UAE chapter. He strongly. believes in total Human Development irrespective of Regions or Classes. He has ardent belief in the evolution/development of therapeutically effective and safe medicines with affordable healthcare for all.

Dr Murli, being a seasoned doctor will look after the Clinical & R&D aspects which shall be the most important engine that fuels almost every activity within a pharmaceutical company. His passion to look after the designing and conducting meaningful and robust clinical trials to improve both patient outcomes and their access to new drugs will change the ongoing dynamics. A dedicated team under his leadership shall oversee the process that takes a molecule from discovery through to clinical development, regulatory approval, and post approval monitoring including preclinical research, early development (phase I trials and proof-of-concept studies as well as late-stage development (phase III and IV trials).

Dr Murli’s organizational zeal shall ensure that disseminated materials on medicines or technologies are factually accurate and in compliance with industry standards [e.g., Association of the British Pharmaceutical Industry (ABPI) Code of Practice also shall facilitate to devise and implement the overall medical strategy, scientific communication strategies and establish educational platforms to translate novel clinical data into practice.

We are confident that Dr. Murli’s team shall lead the engagement with external stakeholders and especially Key Opinion Leaders (KOLs), medical associations, and scientific experts, to learn about current and future medical practice as well as unmet medical needs, and to discuss study designs, published data, potential data gaps, and existing treatment guidelines etc. Dr Murli’s team shall lead the Pharmacovigilance from the front endand visualize new drug applications (NDA) and marketing authorization applications (MAA) to take the status of Mubin Lab's to meet its ambition to make the therapy for Cardiovascular as a honey moon drive.